Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage

A. Papi, F. Blasi, G. W. Canonica, M. Cazzola, S. Centanni, M. P. Foschino Barbaro, A. S. Melani, P. Paggiaro, F. Ricciardolo, A. Rossi, N. Scichilone

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

International guidelines describe asthma control as the main outcome of asthmamanagement. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2- agonists, bymeans of a single inhaler, greatly improves themanagement of the disease. The results of 9multicenter phase III clinical studies demonstrate that the fixed combination of fluticasone propionate/formoterol in a single inhaler is effective in terms of lung function and symptom control. These studies highlight the dose flexibility, safety and tolerability of this new inhaled combination. These characteristicsmeet the recommendations of nternational guidelines, and the preferences of respiratory physicianswho identified these aspects as critical components of a successful asthma therapy. Combination of fluticasone propionate/formoterol in a single inhaler provides potent anti-inflammatory activity of fluticasone propionate and rapid onset of action of the β2-agonist formoterol making this association a viable treatment option both in terms of effectiveness and compliance.

Original languageEnglish
Pages (from-to)695-700
Number of pages6
JournalEuropean Journal of Internal Medicine
Volume25
Issue number8
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Nebulizers and Vaporizers
Asthma
Guidelines
Health Care Costs
Compliance
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Therapeutics
Randomized Controlled Trials
Quality of Life
Safety
Lung
Fluticasone
flutiform

Keywords

  • Asthma control
  • Asthma exacerbations
  • Fixed-combination therapy
  • Fluticasone propionate/formoterol
  • Single-aerosol inhaler

ASJC Scopus subject areas

  • Internal Medicine
  • Medicine(all)

Cite this

Papi, A., Blasi, F., Canonica, G. W., Cazzola, M., Centanni, S., Foschino Barbaro, M. P., ... Scichilone, N. (2014). Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage. European Journal of Internal Medicine, 25(8), 695-700. https://doi.org/10.1016/j.ejim.2014.06.022

Fluticasone propionate/formoterol : A fixed-combination therapy with flexible dosage. / Papi, A.; Blasi, F.; Canonica, G. W.; Cazzola, M.; Centanni, S.; Foschino Barbaro, M. P.; Melani, A. S.; Paggiaro, P.; Ricciardolo, F.; Rossi, A.; Scichilone, N.

In: European Journal of Internal Medicine, Vol. 25, No. 8, 01.10.2014, p. 695-700.

Research output: Contribution to journalArticle

Papi, A, Blasi, F, Canonica, GW, Cazzola, M, Centanni, S, Foschino Barbaro, MP, Melani, AS, Paggiaro, P, Ricciardolo, F, Rossi, A & Scichilone, N 2014, 'Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage', European Journal of Internal Medicine, vol. 25, no. 8, pp. 695-700. https://doi.org/10.1016/j.ejim.2014.06.022
Papi, A. ; Blasi, F. ; Canonica, G. W. ; Cazzola, M. ; Centanni, S. ; Foschino Barbaro, M. P. ; Melani, A. S. ; Paggiaro, P. ; Ricciardolo, F. ; Rossi, A. ; Scichilone, N. / Fluticasone propionate/formoterol : A fixed-combination therapy with flexible dosage. In: European Journal of Internal Medicine. 2014 ; Vol. 25, No. 8. pp. 695-700.
@article{0929a6140d7144bcab5ba7087bb89c91,
title = "Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage",
abstract = "International guidelines describe asthma control as the main outcome of asthmamanagement. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2- agonists, bymeans of a single inhaler, greatly improves themanagement of the disease. The results of 9multicenter phase III clinical studies demonstrate that the fixed combination of fluticasone propionate/formoterol in a single inhaler is effective in terms of lung function and symptom control. These studies highlight the dose flexibility, safety and tolerability of this new inhaled combination. These characteristicsmeet the recommendations of nternational guidelines, and the preferences of respiratory physicianswho identified these aspects as critical components of a successful asthma therapy. Combination of fluticasone propionate/formoterol in a single inhaler provides potent anti-inflammatory activity of fluticasone propionate and rapid onset of action of the β2-agonist formoterol making this association a viable treatment option both in terms of effectiveness and compliance.",
keywords = "Asthma control, Asthma exacerbations, Fixed-combination therapy, Fluticasone propionate/formoterol, Single-aerosol inhaler",
author = "A. Papi and F. Blasi and Canonica, {G. W.} and M. Cazzola and S. Centanni and {Foschino Barbaro}, {M. P.} and Melani, {A. S.} and P. Paggiaro and F. Ricciardolo and A. Rossi and N. Scichilone",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.ejim.2014.06.022",
language = "English",
volume = "25",
pages = "695--700",
journal = "European Journal of Internal Medicine",
issn = "0953-6205",
publisher = "Elsevier B.V.",
number = "8",

}

TY - JOUR

T1 - Fluticasone propionate/formoterol

T2 - A fixed-combination therapy with flexible dosage

AU - Papi, A.

AU - Blasi, F.

AU - Canonica, G. W.

AU - Cazzola, M.

AU - Centanni, S.

AU - Foschino Barbaro, M. P.

AU - Melani, A. S.

AU - Paggiaro, P.

AU - Ricciardolo, F.

AU - Rossi, A.

AU - Scichilone, N.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - International guidelines describe asthma control as the main outcome of asthmamanagement. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2- agonists, bymeans of a single inhaler, greatly improves themanagement of the disease. The results of 9multicenter phase III clinical studies demonstrate that the fixed combination of fluticasone propionate/formoterol in a single inhaler is effective in terms of lung function and symptom control. These studies highlight the dose flexibility, safety and tolerability of this new inhaled combination. These characteristicsmeet the recommendations of nternational guidelines, and the preferences of respiratory physicianswho identified these aspects as critical components of a successful asthma therapy. Combination of fluticasone propionate/formoterol in a single inhaler provides potent anti-inflammatory activity of fluticasone propionate and rapid onset of action of the β2-agonist formoterol making this association a viable treatment option both in terms of effectiveness and compliance.

AB - International guidelines describe asthma control as the main outcome of asthmamanagement. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2- agonists, bymeans of a single inhaler, greatly improves themanagement of the disease. The results of 9multicenter phase III clinical studies demonstrate that the fixed combination of fluticasone propionate/formoterol in a single inhaler is effective in terms of lung function and symptom control. These studies highlight the dose flexibility, safety and tolerability of this new inhaled combination. These characteristicsmeet the recommendations of nternational guidelines, and the preferences of respiratory physicianswho identified these aspects as critical components of a successful asthma therapy. Combination of fluticasone propionate/formoterol in a single inhaler provides potent anti-inflammatory activity of fluticasone propionate and rapid onset of action of the β2-agonist formoterol making this association a viable treatment option both in terms of effectiveness and compliance.

KW - Asthma control

KW - Asthma exacerbations

KW - Fixed-combination therapy

KW - Fluticasone propionate/formoterol

KW - Single-aerosol inhaler

UR - http://www.scopus.com/inward/record.url?scp=84908173011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908173011&partnerID=8YFLogxK

U2 - 10.1016/j.ejim.2014.06.022

DO - 10.1016/j.ejim.2014.06.022

M3 - Article

C2 - 25051902

AN - SCOPUS:84908173011

VL - 25

SP - 695

EP - 700

JO - European Journal of Internal Medicine

JF - European Journal of Internal Medicine

SN - 0953-6205

IS - 8

ER -